Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Oxybutynin hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
What Velariq is Velariq is a solution which contains a medicine called oxybutynin hydrochloride. It works by relaxing the muscles of the bladder and stops sudden muscle contractions (spasms). This helps control the release of water (urine). Velariq solution is to be directly injected into the bladder (intravesical use) through a tube called a catheter. What Velariq is used for –
–
Velariq is used in children from 6 years of age and adults for the treatment of an overactive bladder due to a neurological condition, such as:
Treatment with Velariq must be started and supervised by a doctor specialised in the treatment of overactive bladder due to neurological disorders. 2.
e Velariq
The following section contains information that is important to know before you use this medicine. 1
Do not use Velariq if you are allergic to oxybutynin hydrochloride or any of the other ingredients of this medicine (listed in section 6).
2
–
if you have a rare autoimmune disease called myasthenia gravis that makes the muscles in the body become weak and tire easily. if you have a severe stomach or bowel condition such as severe ulcerative colitis or toxic megacolon (an acute widening of the bowel). if you suffer from glaucoma (increased pressure in the eyes, sometimes sudden and painful with blurred vision or loss of vision). If you have a family history of glaucoma, tell your doctor. if you receive oxygen therapy.
Warnings and precautions Talk to your doctor before using Velariq if: you have an infection of the urinary tract. Your doctor may need to prescribe some antibiotics you are above 65 years old as you may be more sensitive to Velariq you take sublingual nitrates (a medicine which is placed under the tongue to treat chest pain) you have an obstruction of the digestive system, since Velariq might slow down your stomach and bowel movements you have a stomach tear (hiatus hernia) or heartburn you have a nerve disorder called autonomic neuropathy that affects involuntary body functions including heart rate, blood pressure, perspiration and digestion you have problems with memory, language, or thinking abilities you have an overactive thyroid gland which can cause increased appetite, weight loss, or sweating you have narrowing of the blood vessels that supply blood and oxygen to the heart you have heart problems which can cause shortness of breath or ankle swelling you have irregular and/or rapid heartbeat you have high blood pressure you have an enlarged prostate Velariq may reduce the amount of saliva resulting in tooth decay, gum disease, or fungal infection of the mouth (oral thrush). Care must be taken when using Velariq in hot weather or if you have a fever. You should for example stay out of the sun and avoid doing sports in the midday heat. This is because Velariq reduces the amount a person sweats. This can lead to heat exhaustion and heat stroke. Children This medicine is not recommended for use in children under the age of 6 years because safety and efficacy has not been established in this age group. Other medicines and Velariq Tell your doctor if you are taking, have recently taken or might take any other medicines. Using Velariq at the same time as taking other medicines that have similar side effects such as dry mouth, constipation and sleepiness may increase how often and how severe these side effects are experienced. The active substance of Velariq is oxybutynin hydrochloride which may slow the digestive tract and thereby influence the adsorption of other oral medicines, or the use of this medicine together with other medicines may increase the effect of oxybutynin hydrochloride. In particular, tell your doctor if you are taking any of the following medicines: Bisphosphonates (used to treat osteoporosis) and other medicines that can cause or worsen an inflammation of the oesophagus Ketoconazole, itraconazole or fluconazole (used for the treatment of fungal infections) Erythromycin a macrolide antibiotic (used to treat bacterial infections) Biperiden, levodopa, or amantadine (used to treat Parkinson's disease) 3
–
Antihistamines (used in the treatment of allergies such as hay fever) Phenothiazine, butyrophenones or clozapine (used to treat mental illness) Tricyclic antidepressants (used to treat depression) Dipyridamole (used to treat blood clotting problems) Quinidine (used to treat abnormal heart rhythms Atropine and other anticholinergic medicines (used for treatment in stomach disorders such as irritable bowel syndrome)
Velariq with alcohol Velariq may cause sleepiness or blurred vision. Sleepiness may be increased by consumption of alcohol. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. Pregnancy You should not use Velariq if you are pregnant unless your doctor has told you to. Breast-feeding Use of Velariq while breast-feeding is not recommended. Driving and using machines Velariq may cause sleepiness or blurred vision. Take special care when driving or using machinery. Velariq contains contains sodium This medicine contains 3.5 mg sodium (main component of cooking/table salt) in each ml. This is equivalent to 0.18% of the recommended maximum daily dietary intake of sodium for an adult. 3.
Velariq
Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. Dose Your doctor will calculate the correct amount of Velariq needed to treat your overactive bladder. Do not change your dose on your own. During the start of your treatment your doctor will regularly check your bladder function and adjust your dose if necessary. Adolescents (aged 12 years and above), adults and elderly (from 65 years) The recommended starting dose is normally 10 ml of Velariq per day. Children (6 – 12 years) The recommended starting dose is normally 2 ml of Velariq per day.
4
If you have liver or kidney problems Please tell your doctor if you have a liver or kidney problem. Method of administration Your doctor will only prescribe you Velariq if you or your relatives/carer are familiar with the procedure called "Clean Intermittent Catheterisation (CIC)". This is a technique which is done at least six times a day to help empty urine from the bladder using a catheter. CIC stands for Clean Intermittent Catheterisation: Clean: as germ-free as possible Intermittent: done on a regular schedule many times a day Catheterisation: using a catheter, a kind of thin tube, to drain urine out of the bladder Your doctor will train you and/or your relatives/carer on the procedure of CIC and the administration procedure of Velariq. The procedure is as follows: 1. 2. 3. 4. 5. 6. 7. 8.
Prepare a germ-free environmental condition Insert a sterile disposable catheter into the bladder as shown by your doctor Drain the bladder completely via the catheter Take the syringe from the bag Remove the cap from the syringe Screw a stepped tapered luer-lock adapter on the tip of the syringe Connect the catheter to the syringe with the help of the stepped tapered luer-lock adapter Inject your specific amount of solution into the bladder by constant pressing on the plunger of the syringe 9. If your dose is less than 1 syringe (10 ml), the solution that is not used remains in the syringe which has to be brought to a pharmacy for disposal later 10. Remove the catheter The injected solution remains in the bladder until the next catheterisation. Each syringe is for single use only. The urethral catheter, the stepped tapered luer-lock adapter and any unused medicinal product have to be discarded. If you use more Velariq than you should If you accidentally applied more than your prescribed dose, empty the bladder immediately via a catheter. Over dosage can cause symptoms such as restlessness, dizziness, disorders in speech and vision, muscular weakness or faster heartbeat. If you experience one or more of these symptoms, please contact your doctor or the nearest hospital as soon as possible. If you forget to use Velariq If you forget to use a dose at the usual time, use your usual dose in combination with your next catheterisation course. However, if it is nearly time for the next dose, skip the missed dose. Do not use a double dose to make up for a forgotten dose. If you are in doubt, always consult your doctor.
5
If you stop using Velariq If you stop using Velariq, your symptoms and condition of overactive bladder may return or worsen. Always consult your doctor if you are considering stopping the treatment. If you have any further questions on the use of this medicine, ask your doctor. 4.
Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them. The side effects occurring most frequently are typical for this kind of medicine and comprise dry mouth, sleepiness and constipation. The following side effects have been reported for use of oxybutynin hydrochloride, although not all of them have been reported for intravesical use. The frequency of these side effects is not known (frequency cannot be estimated from the available data): Stop taking Velariq and/or contact a doctor right away if: –
you have a (serious) allergic reaction which causes swelling of the face or throat (angioedema)* you feel reduced sweating, leading to overheating in hot environments (heat stroke)* you experience sudden eye pain with blurred vision or loss of vision (glaucoma)*
Tell your doctor or pharmacist if any of the following side effects get serious or lasts longer than a few days: Kidneys –
urinary tract infection occurrence of bacteria in the urine without causing symptoms urgent need to urinate (urinary urgency) protein in urine blood in urine pain when the solution is injected (instilled) into the bladder disorder in passing urine or difficulty to start urinating
Mental illnesses –
seeing or hearing things that are not there (hallucinations) cognitive disorders excessive restlessness and movement (hyperactivity) agitation* mental clouding or confusion difficulty in sleeping agoraphobia (e.g. fear of leaving the house, entering shops, being in crowds and in public places) inability to concentrate anxiety* nightmares* feeling excessively suspicious and distrustful of others (paranoia)* symptoms of depression* becoming dependent on oxybutynin (in patients with history of drug or substance abuse)*
Consciousness –
disorientation
6
–
loss of consciousness listless feeling tired sleepiness a feeling of dizziness or "spinning"
Eyes –
dry eyes abnormal sensation in eye inability of the eye to automatically change focus from distance to near objects which can cause blurred vision, double vision, tired eyes blurring of vision* increased pressure in the eyes*
Heart and blood vessel diseases –
regular but abnormally fast heart rate (supraventricular tachycardia) irregular heartbeat (arrhythmia)* low blood pressure
Skin –
facial flushing rash decreased sweating nighttime sweating itchy, lumpy rash (urticaria)* dry skin* skin that is more sensitive to the sun (photosensitivity)*
Digestive problems –
constipation dry mouth abdominal discomfort lower or upper abdominal pain feeling sick indigestion diarrhoea vomiting* loss of appetite (anorexia)* decreased appetite* difficulty in swallowing (dysphagia)* heartburn* abnormal bloating/swelling together with pain and feeling or being sick (pseudo-obstruction)* change in the sense of taste thirst
General disorders –
chest discomfort feeling cold headache disease of the nervous system (anticholinergic syndrome) fits (seizures) higher level of a hormone called prolactin in the blood. Women might have disruptions in the 7
normal menstrual period or spontaneous flow of breast milk. Men might experience libido or erection disorders as well as an increase of their breast tissue.
will also occur with Velariq that you have been prescribed. One patient experienced an oxygen deficiency during home oxygen therapy (see section 2 under "Do not use Velariq"). Additional side effects in children and adolescents Children may be more sensitive to the effects of this product, particularly the central nervous system and psychiatric side effects. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. 5.
Velariq
Keep this medicine out of the sight and reach of children.
8
Do not use this medicine after the expiry date which is stated on the label of the syringe and the carton after EXP. The expiry date refers to the last day of that month. This medicine does not require any special storage conditions. For single dose use only. Any unused solution must be discarded immediately. Do not throw away any medicines via household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
What Velariq contains The active substance is oxybutynin hydrochloride 1 ml solution contains 1 mg oxybutynin hydrochloride. One scaled prefilled syringe with 10 ml sterile solution contains 10 mg oxybutynin hydrochloride. –
The other excipients are: hydrochloric acid, sodium chloride solution (0.9 %).
What Velariq looks like and contents of the pack Velariq is a clear and colourless solution. It comes as a ready-to-use solution in a 10 ml cycloolefin copolymer prefilled syringe with a synthetic bromobutyl rubber plunger and tip cap. Tray with 12, 96 and 96 (hospital pack) syringes including 12 respectively 96 sterile adapters as application aid. Not all pack sizes may be marketed. Marketing Authorisation Holder & Manufacturer MEDICE Arzneimittel Pütter GmbH & Co. KG Kuhloweg 37 58638 Iserlohn Germany This leaflet was last revised in September 2023.
9
Velariq 1 mg/ml, intravesical solution comes as solution containing 1mg/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Velariq 1 mg/ml, intravesical solution is oxybutynin hydrochloride.
This leaflet reproduces the patient information leaflet approved for Velariq 1 mg/ml, intravesical solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Velariq is indicated for the suppression of neurogenic detrusor overactivity(NDO) in children from 6 years of age and adults, who are managing bladder emptying by clean intermittent catheterisation, not adequately managed with oral anticholinergics (see section 5.1).
Posology
Initial dose adjustment shall be done by a neuro-urologist under close urodynamic control.
There are no fixed rules for the dose regimen as high interindividual differences in bladder pressure and doses required to improve neurogenic detrusor overactivity exist. The dose regimen (doses and timings) must therefore be determined individually according to the patient´s need.
Individual dosages will be applied to control uro-dynamic parameters sufficiently (maximum detrusor pressure < 40 cm H2O) aiming at complete inhibition of neurogenic detrusor overactivity.
In the course of intravesical oxybutynin therapy, urodynamic parameters shall be controlled in regular intervals as defined by the attending urologist.
Paediatric population
The safety and efficacy of oxybutynin hydrochloride in children aged 0 to 5 years of age have not yet been established.
Dose recommendations in the following age groups
The dose recommendations have been calculated according to the body weight percentiles of the different age groups (table 1)
Table 1: Dose recommendations in all age groups
Age group
Age [years]
Recommended daily starting dose [mg]
Recommended total daily dose [mg]
Children
6 - 12
2
2 - 30
Adolescents
12 - 18
10
10 - 40
Adults
19 - 65
10
10 - 40
Elderly
from 65
10
10 - 30
If higher doses than the starting dose are considered necessary, the dose should be increased using a step-wise approach until neurogenic detrusor overactivity is sufficiently controlled to allow close monitoring of both efficacy and safety. The required daily maintenance doses may be divided into several applications (table 2 and 3). Given a number of six clean intermittent catheterisations (CICs) per day, the following dose scheme is recommended:
Table 2: Recommended dose scheme for 2 mg starting doses (children from 6 - 12 years)
Daily dose
[mg]
Administered dose per application [mg]
CIC 1
CIC 2
CIC 3
CIC 4
CIC 5
CIC 6
2
2
-
-
-
-
-
5
5
-
-
-
-
-
10
5
-
5
-
-
-
15
5
-
5
-
5
-
20
10
-
10
-
-
-
30
10
-
10
-
10
-
Table 3: Recommended dose scheme for 10 mg starting doses (adolescents from 12 years and above, adults and elderly)
Daily dose
[mg]
Administered dose per application [mg]
CIC 1
CIC 2
CIC 3
CIC 4
CIC 5
CIC 6
10
5
-
5
-
-
-
20
10
-
10
-
-
-
30
10
-
10
-
10
-
40
10
10
10
-
10
-
Elderly (from 65 years)
As with other anticholinergic drugs caution should be observed in frail and elderly patients, especially if doses higher than 30 mg per day are considered as required (see section 4.4).
Hepatic or renal impairment
Velariq should be used with caution in patients with hepatic or renal impairment. The use of Velariq in those patients should be carefully monitored and dose reductions may be needed.
Method of administration
Intravesical use.
To ensure safe and effective treatment, patients must be familiar with the procedure of clean intermittent catheterisation (CIC). The patients and/or relative, carer shall be trained on CIC and the administration procedure by specialised health care professionals.
As soon as the environmental conditions are aseptic, a sterile disposable urethral catheter is inserted into the bladder. The bladder has to be drained completely before the instillation.
The scaled prefilled syringe is taken from the bag and the cap is removed from the syringe.
A stepped tapered luer-lock adapter is screwed on the tip of the syringe. With the help of the stepped tapered luer-lock adapter, the syringe is connected to the catheter. The required amount of the oxybutynin solution is instilled into the bladder by constant pressing on the plunger of the syringe.
If the application of less than 10 ml (one syringe content) is required, the solution that is not used remains in the syringe which has to be brought to a pharmacy for disposal later.
After the instillation the catheter is removed.
The instilled solution remains in the bladder until the next catheterisation.
Any unused medicinal product, the urethral catheter and the stepped tapered luer-lock adapter have to be discarded.
The duration of treatment depends on the symptoms, the underlying disease and / or the treatment goal and is determined by the treating physician.
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Severe gastro-intestinal condition (e. g. severe ulcerative colitis and toxic megacolon).
- Myasthenia gravis.
- Narrow angle glaucoma and in patients who are at risk for these conditions.
- Concomitant oxygen therapy.
If urinary tract infection is present, an appropriate antibacterial therapy should be started.
Velariq should be used with caution in elderly patients, who may be more sensitive to the effects of centrally acting anticholinergics.
Psychiatric and central nervous system (CNS) anticholinergic events like sleep disorders (e.g. insomnia) and cognitive disorders have been associated with oxybutynin use, especially in elderly patients. Caution should be exercised when oxybutynin is administrated concomitantly with other anticholinergic medicines (see also section 4.5). If a patient experiences such events, drug discontinuation should be considered.
Sublingual nitrates may fail to dissolve under the tongue owing to dry mouth, resulting in reduced therapeutic effect.
The use/administration of oxybutynin products may warrant the following cautionary statements:
Gastrointestinal disorders
Anticholinergic medicinal products may decrease gastrointestinal motility and should be used with caution in patients with gastrointestinal obstructive disorders because of the risk of gastric retention. They should also be used with caution in patients who have hiatus hernia/gastro-oesophageal reflux.
Anticholinergic medicinal products should be used with caution in patients who have autonomic neuropathy or cognitive impairment.
Patients should be informed that heat prostration (fever and heat stroke due to decreased sweating) can occur when anticholinergics such as oxybutynin are used in a hot environment.
Oxybutynin may exacerbate the symptoms of hyperthyroidism, coronary heart disease, congestive heart failure, cardiac arrhythmias, tachycardia, hypertension and prostatic hypertrophy.
Oxybutynin may lead to suppressed salivary secretions which could result in dental caries, parodontosis or oral candidiasis.
Paediatric population
In children Velariq should be used with caution as they may be more sensitive to the effects of the product, particularly the CNS and psychiatric adverse reactions.
This medicinal product contains 3.5 mg sodium per ml, equivalent to 0.18% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
Anticholinergic agents may potentially alter the absorption of some concomitantly administered medicinal products due to anticholinergic effects on gastrointestinal motility.
Anticholinergic medicinal products should be used with caution in patients who are concurrently taking medicinal products (such as bisphosphonates) that can cause or exacerbate oesophagitis.
Oxybutynin is metabolised by cytochrome P 450 isoenzyme CYP 3A4. By applying oxybutynin intravesically, this first-pass metabolism is mainly circumvented. However, interactions with medicinal products that inhibit cytochrome P 450 isoenzyme CYP 3A4 cannot be ruled out. This should be borne in mind when using azole antifungals (e.g. ketoconazole) or macrolide antibiotics (e.g. erythromycin) concurrently with oxybutynin.
The anticholinergic activity of oxybutynin is increased by concurrent use of other anticholinergics or medicinal products with anticholinergic activity, such as amantadine and other anticholinergic antiparkinsonian medicinal products (e.g. biperiden, levodopa), antihistamines, antipsychotics (e.g. phenothiazines, butyrophenones, clozapine), quinidine, tricyclic antidepressants, atropine and related compounds like atropinic antispasmodics, dipyridamole.
Oxybutynin may antagonise prokinetic therapy.
Pregnancy
There are no data on the intravesical use of oxybutynin in pregnant women. Studies in animals have shown minor reproductive toxicity (see section 5.3). Velariq should not be used during pregnancy unless the clinical condition of the woman requires treatment.
Breast-feeding
Available information shows that oxybutynin is excreted in milk of rats, but it is not known whether oxybutynin is excreted in human milk. Use of oxybutynin is not recommended during breast-feeding.
Fertility
Data on possible effects of the use of oxybutynin on human male and female fertility are not available.
Because Velariq may produce somnolence, or accommodation disorders, patients should be advised to exercise caution when driving or using machinery.
Patients should be informed that alcohol may enhance the drowsiness caused by anticholinergic agents such as oxybutynin.
Undesirable effects observed with oxybutynin hydrochloride such as dry mouth, somnolence, and constipation mainly reflect the typical anticholinergic properties of the active ingredient.
Table 4 includes adverse reactions from clinical trials with intravesical use of oxybutynin hydrochloride. The adverse reactions are classified by System Organ Class and frequency, using the following convention: Very common (≥ 1/10), Common (≥1/100 to < 1/10), Uncommon (≥ 1/1,000 to < 1/100), Rare (≥ 1/10,000 to < 1/1,000), Very rare (< 1/10,000), Not known (cannot be estimated from the available data).
Table 4: Adverse reactions from clinical trials with intravesical use of oxybutynin hydrochloride
System Organ Class
Adverse reaction
Frequency
Infections and infestations
Urinary tract infection, asymptomatic bacteriuria
unknown
Endocrine disorders
Hyperprolactinaemia, prolactin increase (once-only)
unknown
Psychiatric disorders
Listless, hallucinations, cognitive disorders, hyperactivity, insomnia, agoraphobia, disorientation
unknown
Nervous system disorders
Disturbance in attention, dizziness, headache, somnolence, fatigue, dysgeusia, depressed level of consciousness, loss of consciousness, anticholinergic syndrome, seizure
unknown
Ear and labyrinth disorders
Vertigo
unknown
Eye disorders
Dry eye, abnormal sensation in eye, accommodation disorder
unknown
Cardiac disorders
Supraventricular tachycardia
unknown
Vascular disorders
Hypotension, facial flushing
unknown
Gastrointestinal Disorders
Constipation, dry mouth, abdominal discomfort, abdominal pain lower, abdominal pain upper, nausea, dyspepsia, diarrhoea
unknown
Skin and subcutaneous tissue disorders
Hypohidrosis, rash, nocturnal sweating
unknown
Renal and urinary disorders
Micturition urgency, proteinuria, haematuria, micturition disorder
unknown
General disorders and administration site conditions
Instillation site pain, thirst, chest discomfort, feeling cold
unknown
One patient experienced decreased oxygen saturation during home oxygen therapy (see section 4.3).
Paediatric population
Children may be more sensitive to the effects of the product, particularly the CNS and psychiatric adverse reactions.
Adverse reactions known to be associated with anticholinergic therapy, but not observed with intravesical use of oxybutynin during clinical studies are vomiting, anorexia, decreased appetite, dysphagia, gastroesophageal reflux disease, pseudo-obstruction in patients at risk (elderly or patients with constipation and treated with other drugs that decrease intestinal motility), confusional state, agitation, anxiety, nightmares, paranoia, symptoms of depression, dependence to oxybutynin (in patients with history of drug or substance abuse), arrhythmia, heat stroke, angle closure glaucoma, ocular hypertension, dry skin, angioedema, urticaria, photosensitivity, hypersensitivity.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
No cases of overdose have been reported with intravesical use of oxybutynin.
Symptoms
The symptoms of overdosage with oxybutynin progress from an intensification of the usual side effects of CNS disturbances (from restlessness and excitement to psychotic behaviour), circulatory changes (flushing, fall in blood pressure, circulatory failure etc.), respiratory failure, paralysis and coma.
Treatment
The bladder should be emptied immediately via the catheter.
In case of overdose, patients should be closely monitored and treated symptomatically.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Velariq 1 mg/ml, intravesical solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.